Correspondingly, the serum CCL2 and CCL5 levels were highest in the mice injected with MDA-MB-231/CAFs shNC and MDA-MB-231/CAFs sh lncSNHG5/ZNF281, and decreased serum CCL2 and CCL5 levels were observed in tumor-bearing mice injected with MDA-MB-231/CAFs shRNAs against lncSNHG5 and ZNF281 (CAFs/sh lncSNHG5, CAFs/shZNF281; Figure 7D-E). This evidence concerns the gene CCL2 and neoplasm.